![Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) Drug Overview 2019- Product Image](http://www.researchandmarkets.com/product_images/8219/8219237_500px_jpg/triumeq_[dolutegravir_abacavir_lamivudine]_viiv_healthcare_drug_overview_2019.jpg)
Drug Overview
Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.
Triumeq is the first and only single-tablet regimen to have demonstrated a superior rate of virologic suppression compared to Atripla ([efavirenz + emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead). Its strong efficacy, attractive tolerability profile, and the high barrier to resistance offered by its Tivicay (dolutegravir; ViiV Healthcare) component have resulted in Triumeq generating blockbuster worldwide sales of $3.4bn in 2018. However, multiple factors limit its future growth potential, including intense competition from Gilead’s rival integrase strand transfer inhibitor-containing STR Biktarvy ([bictegravir + emtricitabine + tenofovir alafenamide (TAF)]), physician preference for the TAF + emtricitabine backbone, and the threat of generic incursion.
Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.
Triumeq is the first and only single-tablet regimen to have demonstrated a superior rate of virologic suppression compared to Atripla ([efavirenz + emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead). Its strong efficacy, attractive tolerability profile, and the high barrier to resistance offered by its Tivicay (dolutegravir; ViiV Healthcare) component have resulted in Triumeq generating blockbuster worldwide sales of $3.4bn in 2018. However, multiple factors limit its future growth potential, including intense competition from Gilead’s rival integrase strand transfer inhibitor-containing STR Biktarvy ([bictegravir + emtricitabine + tenofovir alafenamide (TAF)]), physician preference for the TAF + emtricitabine backbone, and the threat of generic incursion.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
